Research ArticleArticle
Comparative Evaluation of Plasma Bile Acids, Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects
Hong Shen, Weiqi Chen, Dieter M. Drexler, Sandhya Mandlekar, Vinay K. Holenarsipur, Eric E. Shields, Robert Langish, Kurex Sidik, Jinping Gan, W. Griffith Humphreys, Punit Marathe and Yurong Lai
Drug Metabolism and Disposition August 2017, 45 (8) 908-919; DOI: https://doi.org/10.1124/dmd.117.075531
Hong Shen
Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India
Weiqi Chen
Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India
Dieter M. Drexler
Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India
Sandhya Mandlekar
Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India
Vinay K. Holenarsipur
Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India
Eric E. Shields
Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India
Robert Langish
Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India
Kurex Sidik
Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India
Jinping Gan
Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India
W. Griffith Humphreys
Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India
Punit Marathe
Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India
Yurong Lai
Pharmaceutical Candidate Optimization (H.S., W.C., R.L., J.G., W.G.H., P.M., Y.L.) and Global Biometrics Sciences (K.S.), Bristol-Myers Squibb Company, Princeton, New Jersey; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Wallingford, Connecticut (D.M.D., E.E.S.); Bristol-Myers Squibb India Pvt. Ltd. (S.M.) and Syngene International Ltd. (V.K.H.), Biocon BMS R&D Center, Bangalore, India
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleArticle
Endogenous Biomarkers of OATP Inhibition
Hong Shen, Weiqi Chen, Dieter M. Drexler, Sandhya Mandlekar, Vinay K. Holenarsipur, Eric E. Shields, Robert Langish, Kurex Sidik, Jinping Gan, W. Griffith Humphreys, Punit Marathe and Yurong Lai
Drug Metabolism and Disposition August 1, 2017, 45 (8) 908-919; DOI: https://doi.org/10.1124/dmd.117.075531
Research ArticleArticle
Endogenous Biomarkers of OATP Inhibition
Hong Shen, Weiqi Chen, Dieter M. Drexler, Sandhya Mandlekar, Vinay K. Holenarsipur, Eric E. Shields, Robert Langish, Kurex Sidik, Jinping Gan, W. Griffith Humphreys, Punit Marathe and Yurong Lai
Drug Metabolism and Disposition August 1, 2017, 45 (8) 908-919; DOI: https://doi.org/10.1124/dmd.117.075531
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement